Results 271 to 280 of about 857,410 (384)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

Acta Pharmaceutica Sinica B, 2015
Lihua Huang, Liwu Fu
semanticscholar   +1 more source

Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma. [PDF]

Cancer Immunol Immunother
Xu S, Zheng R, Sun C, Sa R.
europepmc   +1 more source

The Tyrosine Kinase Hck Is an Inhibitor of HIV-1 Replication Counteracted by the Viral Vif Protein [PDF]

, 2001
Ghérici Hassaı̈ne, M Courcoul, Gilles Bessou, Yves Barthalay, Christophe Picard, Daniel Olive, Yves Collette, Robert Vigne, Étienne Decroly   +8 more
openalex   +1 more source

Loss of STARD7 Triggers Metabolic Reprogramming and Cell Cycle Arrest in Breast Cancer

Advanced Science, EarlyView.
Breast cancer cells undergo metabolic and transcriptomic reprogramming to support aberrant cell proliferation. Their mitochondria rely on the transfer of phosphatidylcholine from the endoplasmic reticulum to their membranes by STARD7, a candidate upregulated in breast cancer, to be functional.
Ewelina Dondajewska, Paula Allepuz‐Fuster, Chloé Maurizy, Alexandre Hego, Sandra Ormenese, Quentin Lion, Arnaud Blomme, Pierre Close, Arnaud Lavergne, Latifa Karim, Marc Thiry, Ivan Nemazanyy, Roopesh Krishnankutty, Jair Marques Jr, Alex von Kriegsheim, Nathaniel F. Henneman, Ganna Panasyuk, Kateryna Shostak, Alain Chariot   +18 more
wiley   +1 more source

Expression of Concern: Assessing clinical and morphological features of megalotrichosis induced by Tyrosine kinase inhibitors versus Prostaglandins analogues. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Lauryl Gallate Inhibits the Activity of Protein Tyrosine Kinase c-Src Purified from Human Platelets [PDF]

, 2001
Carmen Palacios, Constantino Cespón, Cristina Martín de la Vega, Garbiñe Roy, Antonio Serrano, Matilde Salinas, Pedro González-Porqué   +6 more
openalex   +1 more source

Identification and Drug Screening of Single Cells from Human Tumors on Semiconductor Chip for Cancer Precision Medicine

Advanced Science, EarlyView.
The study innovatively integrates single‐cell electric impedance identification and drug screening on a semiconductor chip, addressing tumor heterogeneity limitations. The system achieves label‐free cancer cell recognition while concurrently evaluating drug efficacy on cancer cells and toxicity on noncancerous cells.
Wenhao Hui, Ka‐Meng Lei, Yingying Liu, Xinru Huang, Yunlong Zhong, Xiaojun Chen, Mingji Wei, Jie Yan, Ren Shen, Pui‐In Mak, Rui P. Martins, Shuhong Yi, Ping Wang, Yanwei Jia   +13 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET-Guided Verification. [PDF]

CPT Pharmacometrics Syst Pharmacol
van der Gaag S, Jordens T, Yaqub M, Grijseels R, van Valkengoed DW, de Langen EN, van den Broek R, Thijssen VLJL, de Langen AJ, Kouwenhoven MCM, Bahce I, Westerman BA, Hendrikse NH, Bartelink IH.   +13 more
europepmc   +1 more source

LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5

Advanced Science, EarlyView.
Li et al. innovatively map the kinase‐substrate network in esophageal cancer metastasis. Their study demonstrates that LIM domain kinase 1 (LIMK1) and Cyclin‐dependent kinase 5 (CDK5) synergistically increase the phosphorylation of β‐catenin, thereby activating the Wnt/β‐catenin signaling pathway to promote esophageal cancer metastasis.
Shu‐Jun Li, Zhuo‐Ran Liang, Zhi‐Chao Liu, Xue‐Ping Luo, Jun‐Yi Li, Xiao‐Mei Yu, Xuan‐Zhang Huang, Yan He, Tao‐Yang Xu, Jiao‐Jiao Xu, Shao‐Cong Peng, Yu‐Xiang Song, Yan He, Xiao‐Wan Zhuang, Can‐Can Zheng, Fan Zhang, Alfred King‐Yin Lam, Wei Dai, Ming‐Liang He, Bo Liu, Qi Zhao, Guo‐Liang Lu, Jin‐Bao Liu, Zhen‐Ning Wang, Zhi‐Gang Li, Ze‐Xian Liu, Wen‐Wen Xu, Bin Li   +27 more
wiley   +1 more source

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. [PDF]

CPT Pharmacometrics Syst Pharmacol
Demin O, Ou Y, Kolesova G, Shchelokov D, Stepanov A, Musatova V, Sahasranaman S, Zhao Y, Liu X, Tang Z, Hanley WD.   +10 more
europepmc   +1 more source